在社区获得的严重肺炎中使用类固醇
Sachin Ananth1, Alexander G Mathioudakis2,3, Jan Hansel2,3
1London North West University Healthcare NHS Trust, London, UK.
Breathe (Sheffield, England)
|October 3, 2024
概括
皮在治疗严重的社区获得性肺炎 (CAP) 中表现有前途,减少死亡率和干预的需要. 需要进一步的研究来确认CAP的长期益处和最佳类固醇剂量.
科学领域:
- 临界护理医学 临界护理医学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于在严重的社区获得性肺炎 (CAP) 中使用类固醇存在相互矛盾的证据.
- 之前的试验受到小样本大小的限制.
- 两个大型试验ESCAPe和Cape COD提供了新的见解.
研究的目的:
- 为了比较不同类固醇治疗方案在严重CAP中的疗效.
- 为了评估类固醇的时间管理的影响.
- 根据患者特征分析结果.
主要方法:
- ESCAPe试验:甲基普雷迪尼索隆在接受治疗后72-96小时开始.
- CAPE COD试验:在严重的CAP发展的24小时内启动皮.
- 综合死亡率,输管率和冲击率的比较.
主要成果:
- 在死亡率或二次结果方面,ESCAPe没有发现任何显著差异.
- 在CAPE COD的研究中,使用皮的28天死亡率有所降低.
- 皮还降低了CAPE COD中输管或血管压缩剂依赖性休克的风险.
结论:
- 在严重CAP的24小时内开始用皮质可能会改善结果.
- 类固醇类型,时间和患者人群 (例如糖尿病) 的差异影响了试验结果.
- 需要进一步的研究,以获得长期的结果和在严重的CAP中最佳的类固醇剂量策略.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...


